Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes
Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.
Authors
- Odelia Cooper (ORCID: https://orcid.org/0000-0001-5955-8242)
- Ning-Ai Liu
- Daniel Richard Gomez (ORCID: https://orcid.org/0009-0003-8617-3868)
- Adam N. Mamelak (ORCID: https://orcid.org/0000-0002-4245-6431)
- Artak Labadzhyan (ORCID: https://orcid.org/0000-0002-8288-6698)
- R.A. Fox (ORCID: https://orcid.org/0000-0002-9841-9760)
- Anat Ben Shlomo
- Vivien Bonert
- Yujie Cui
- Yaakov Rosenberg
Institutions
- Cedars-Sinai Medical Center (US)
Publication Details
- Journal
- Pituitary
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1007/s11102-025-01628-8
- Citations
- 1
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 30.73